Shop › Growth Hormone › CJC-1295 (no DAC) + Ipamorelin 10mg 10mg (5mg+5mg)

thepeptide.ca testides coa cjc/ipamorelin 10mg

Growth HormoneVerified lot

CJC-1295 (no DAC) + Ipamorelin 10mg 10mg (5mg+5mg)

Name: CJC-1295 (no DAC) + Ipamorelin 10mg
Brand: ThePeptide
SKU: CJC-IPAM-10MG
Price: 79.0 CAD
Availability: InStock

GHRH Analogue + Ghrelin Agonist Blend

$79.00CAD · $7.90 / mg

In stock · 16 available · ships within 48 h from BC

3+ 10% off5+ 15% off10+ 20% offany mix

Lab result for this lotVerified · Testides

95.80%purity · HPLC-UV 214 nm

Measured content10.08 mg (CJC 4.74 + Ipa 5.34)

Lotcjc10-0626-02

Testing labTestides, Toronto

Reported2 Oct 2026

Named-component HPLC-UV at 214 nm — CJC-1295 (no DAC) 4.74 mg and Ipamorelin 5.34 mg, 10.08 mg total vs 10 mg label (100.8%). Identity conforms. Enter report ARUA-CJCN-10-092026 at testides.com/verify to see the lab's own record and chromatogram.

Verify

✓ Testides-verified — lot cjc10-0626-02

Our confirmatory HPLC-UV is in. Testides, Toronto, report ARUA-CJCN-10-092026, run 25 September 2026 and issued 2 October 2026: 95.80% named-component purity at 214 nm, 10.08 mg total content against a 10 mg label (100.8%), identity Conforms.

On a blend the purity figure that means anything is the combined share of both named components, not a single main peak. Ipamorelin accounts for 81.08% of total integrated area and CJC-1295 (no DAC) for 14.72% — 95.80% together, with the largest single impurity at 2.25%. Component amounts: CJC-1295 (no DAC) 4.74 mg (94.8% of its 5 mg share, read against the laboratory's calibration curve) and ipamorelin 5.34 mg (106.8%, estimated by peak area — the laboratory holds no curve for ipamorelin). Full reasoning below.

Testides verifies this report by the document itself: upload the original PDF at testides.com/verify and it is checked against the laboratory's released copy. Email info@thepeptide.ca and we will send you the PDF · All lab results

This is CJC-1295 without DAC blended with ipamorelin, 5 mg of each in a single 10 mg vial of lyophilised powder — and CJC-1295 without DAC is the same molecule as modified GRF (1-29), not a different compound that shares a name.

That equivalence is the most confused point in this category, so it is worth stating without hedging. CJC-1295 no DAC, mod GRF (1-29) and CJC-1295 DAC-free are three names for one 29-residue peptide: CAS 863288-34-0, formula C152H252N44O42, molecular weight 3367.95 g/mol, C-terminally amidated. Vendors listing them as separate SKUs, or calling one a newer version of the other, are selling the same peptide twice.

Structurally it is sermorelin — native human GRF(1-29)NH₂ — carrying four substitutions: D-Ala², Gln⁸, Ala¹⁵ and Leu²⁷, only one of which has a primary source behind its rationale. The D-Ala² substitution blocks dipeptidyl peptidase-4 cleavage at the Tyr¹-Ala² bond, the dominant plasma inactivation route for GHRH peptides; Jetté et al. (2005) assayed DPP-IV stability directly. The other three are consistent with removing a deamidation liability at Asn⁸ and an oxidation liability at Met²⁷ and with improving potency, but no primary source states each rationale individually.

DAC is a real covalent addition, not a marketing suffix. Drug Affinity Complex is an Nε-maleimidopropionyl group on a lysine appended at position 30; in vivo the maleimide binds Cys34 of serum albumin, tethering the peptide to a long-circulating carrier. The DAC form therefore has 30 residues, CAS 446262-90-4 and a molecular weight of 3647.25 — a mass difference of roughly 280 Da, which is how a buyer tells the two apart on a COA.

The second component is ipamorelin, development code NNC 26-0161: a pentapeptide, CAS 170851-70-4, formula C38H49N9O5, molecular weight 711.87 g/mol, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂ — five residues, two non-proteinogenic (α-aminoisobutyric acid and 2-naphthylalanine) and two D-amino acids.

The two are blended because they act on different receptors through different second messengers on the same pituitary cell: GHRH-R is Gs-coupled through cAMP and PKA, GHS-R1a is Gq-coupled through phospholipase C, IP₃ and calcium. One converging output — a basis for a hypothesis, not evidence of a result.

Read this before any claim you see about CJC-1295 without DAC

Every substantive human and animal study of CJC-1295 used the DAC version — Jetté 2005 (PMID 15817669), Teichman 2006 (PMID 16352683), Alba 2006 (PMID 16822960). There is no published human pharmacokinetic or efficacy trial of the no-DAC molecule at all. The "~30 minute half-life" quoted for it across the industry has no primary human PK study behind it.

The subtler version of the error: a page sells the no-DAC peptide, then cites Teichman's multi-day half-life and sustained GH-elevation figures. Those are DAC figures, following from albumin tethering — the exact feature this molecule lacks. Vendors who cite their sources do this too.

We supply this vial strictly as a laboratory reagent and publish no dosing, route, schedule or protocol information. Neither compound is approved anywhere, and the combination has never been studied in either form.

For laboratory and research use only. Not for human consumption, veterinary use, or therapeutic application. Not approved by Health Canada. We do not provide preparation, dilution or administration guidance for any compound we sell.

Read the full research guide →

ProductCJC-1295 (no DAC) + Ipamorelin blend, 10 mg total, lyophilised powder

Component 1 — namesCJC-1295 without DAC = modified GRF (1-29) = CJC-1295 DAC-free. One molecule

Component 1 — CAS863288-34-0

Component 1 — formula / MWC152H252N44O42, 3367.95 g/mol

Component 1 — sequence29 residues, C-terminally amidated. Sermorelin with four substitutions: D-Ala², Gln⁸, Ala¹⁵, Leu²⁷

Component 2 — namesIpamorelin; development code NNC 26-0161

Component 2 — CAS170851-70-4

Component 2 — formula / MWC38H49N9O5, 711.87 g/mol

Component 2 — sequence5 residues, C-terminally amidated — Aib-His-D-2-Nal-D-Phe-Lys-NH₂. Two non-proteinogenic residues (Aib, 2-naphthylalanine) and two D-amino acids

DAC vs no-DAC — the checkNo DAC (this product): CAS 863288-34-0, MW 3367.95, 29 residues.
With DAC: CAS 446262-90-4, MW 3647.25, 30 residues, Nε-maleimidopropionyl-Lys³⁰ binding Cys34 of serum albumin in vivo.
Difference ≈ 280 Da — the figure to look for on a COA.

Compound classesGHRH-R agonist (Gs–cAMP–PKA) blended with a GHS-R1a agonist (Gq–PLC–IP₃–Ca²⁺)

Assay statusTestides-verified — 95.80% named-component purity, identity conforms, 10.08 mg total (100.8% of a 10 mg label)

Purity95.80% — the combined named-component share at 214 nm (ipamorelin 81.08% + CJC-1295 no DAC 14.72%). Reported this way because a two-API vial has two product peaks; a single main-peak figure would be undefined

Testing laboratoryTestides, Toronto — report ARUA-CJCN-10-092026, run 25 Sep 2026, issued 2 Oct 2026 (our confirmatory HPLC-UV). Earlier assay: Janoshik Analytical #209639, July 2026. Both indexed on our lab results page

Confirmatory statusComplete — Testides confirmatory HPLC-UV received 2 October 2026. Result rests on a single injection; we claim no accreditation or ISO status

Research applicationsDual-receptor somatotroph pharmacology (GHRH-R versus GHS-R1a); cAMP and calcium-flux assays; pathway-convergence models; DPP-4 and plasma-peptidase stability work; GHS-R1a selectivity screening; two-analyte LC-MS/MS method development; DAC versus no-DAC identity discrimination

Related compoundsIpamorelin 10mg · Tesamorelin 10mg

Ships fromBritish Columbia, Canada. Free tracked shipping Canada-wide, no minimum order, dispatched within 48 hours Monday to Friday

Intended useLaboratory research only, in vitro and preclinical. Not a drug; not for human or veterinary use

Vial contents10 mg label weight, sealed vial, no excipient

Current lotcjc10-0626-02

1. No human pharmacokinetic or efficacy trial of CJC-1295 without DAC exists. Jetté 2005, Teichman 2006 and Alba 2006 all used the DAC version, so the no-DAC molecule is uncharacterised in humans. The "~30 minute half-life" appears on nearly every page selling this peptide, usually uncited; inferring it from D-Ala²-conferred DPP-4 resistance is a plausible expectation, not a measurement, so we quote no half-life. Teichman's multi-day half-life and sustained GH-elevation findings exist because DAC tethers the peptide to albumin. 2. The blend itself has never been studied in either CJC-1295 form. 3. Ipamorelin's only human efficacy trial missed its primary endpoint. Beck et al. (2014, PMID 25331030), phase 2 randomised, double-blind, placebo-controlled, 114 participants with postoperative ileus: 25.3 hours versus 32.6 hours, p = 0.15. Development stopped afterwards. It is a real, appropriately blinded trial, and it is negative. The preclinical record stands separately: Raun et al. (1998, PMID 9849822) established selectivity in rats and swine, which is animal pharmacology, not human efficacy. 4. The CJC-1295 programme ended in 2006. ConjuChem took CJC-1295 with DAC into phase II for HIV-associated lipodystrophy; on 17 July 2006 the 192-participant study was halted after a participant at an Argentine site died following his eleventh injection. Established: the death occurred; the study was halted on 17 July 2006; the attending physician concluded the death was not related to the study drug; the programme was terminated as a precaution. CJC-1295 was never revived and has never been approved anywhere. Not established, in either direction: no published follow-up establishes causation. We do not imply the drug caused the death, and we do not present it as cleared. None of this makes the material uninteresting as a reagent — an unresolved mechanism with a well-defined two-receptor structure is what preclinical work is for. It does mean anything framed as "clinically proven" or "demonstrated synergy" asserts what the literature does not contain.

Health Canada has named both of these compounds. A public advisory dated 9 April 2026 on injectable peptides bought online names both CJC-1295 and ipamorelin, states that peptides of this kind are generally regulated as prescription drugs in Canada, and says explicitly that "research use only" labelling does not make these products legal or exempt from regulatory requirements. We publish that knowing it cuts against our own interest, because the alternative is pretending a disclaimer is a legal shield after the regulator has said it is not. Our research framing therefore has to be real rather than decorative: we supply this vial as a reagent, publish no dosing or protocol information, and make no human-use claims. Whether a particular purchase or use is lawful in your circumstances is a question for a Canadian regulatory lawyer, not a product page. FDA's position on compounded CJC-1295 is worth quoting directly: "may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to... peptide-related impurities and API characterization. FDA has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction." Two of those concerns, impurity profiling and API characterisation, are analytical rather than clinical, which is why lot-specific third-party testing is the minimum standard here. WADA: both are prohibited at all times, and both are non-Specified, under S2.2.4 — CJC-1295 under "GHRH and its analogues", alongside CJC-1293, sermorelin and tesamorelin; ipamorelin under "growth hormone secretagogues and their mimetics". One detail catches people out: the List names "CJC-1295" with no DAC qualifier, so both forms are covered. Athletes in tested sport should obtain a written determination from their national anti-doping organisation rather than rely on any vendor's reading. Approval status: CJC-1295 has never been approved by any regulator anywhere, in either form, and ipamorelin has no approved product. The vial on this page is an unapproved research reagent, and none of the above is legal advice.

For laboratory and research use only. Not for human consumption, veterinary use, or therapeutic application. Not approved by Health Canada.

CJC-1295 (no DAC) + Ipamorelin 10mg 10mg (5mg+5mg)$79.00 · 95.80% pure

CJC-1295 (no DAC) + Ipamorelin 10mg 10mg (5mg+5mg)

More growth hormone peptides